NEW YORK (GenomeWeb News) – Three Massachusetts research hospitals will evaluate Protein Forest’s bioinformatics software in separate disease studies, the company said Friday.
The Whitehead Institute, the Proteomics and Mass Spectrometry Facility at the University of Massachusetts Medical School, and Harvard Medical School will use the company’s Mass Spec Results Analysis Tool (MSRAT) to study data generated using the company’s digital ProteomeChip system.
The studies will involve seeking biomarkers for glial tumors, identifying prostate cancer markers in urine, and studying diseases linked to MHC class I and class II peptides from T cells, the Lexington, Mass.-based company said.
The MSRAT software is used to help correlate protein expression, post-translational modifications and pl isoformes with diseases from mass spectrometry-based proteomics studies, and it uses visualization tools such as histograms, Venn diagrams, differential heat maps, and virtual 2D gel maps to assist in interpreting MS data.
Financial terms of the agreements were not released.